help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on April 7, 2004, doi:10.1164/rccm.200312-1683OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online  Supplement
Right arrow All Versions of this Article:
200312-1683OCv1
169/12/1322    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ebstein, F.
Right arrow Articles by Grégoire, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebstein, F.
Right arrow Articles by Grégoire, M.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 1322-1330, (2004)
© 2004 American Thoracic Society

Original Article

Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells

Frédéric Ebstein, Carole Sapede, Pierre-Joseph Royer, Marie Marcq, Catherine Ligeza-Poisson, Isabelle Barbieux, Laurent Cellerin, Gérard Dabouis and Marc Grégoire

Unité INSERM U601, Institut de Biologie, and Service d'Oncologie Thoracique et Digestive, CHU Hôtel Dieu, Nantes, France

Correspondence and requests for reprints should be addressed to Marc Grégoire, Ph.D., INSERM U601, Institut de Biologie, 44093 Nantes Cedex 01, France. E-mail: marc.gregoire{at}nantes.inserm.fr

Malignant pleural mesothelioma is an uncommon tumor largely confined to the thoracic cavity, which is resistant to conventional therapies, therefore prompting an intensive search for effective treatment alternatives. This study focuses on dendritic cell (DC) vaccination for malignant pleural mesothelioma and evaluates the in vitro efficacy of antigen-loaded DC-based vaccines for the induction of major histocompatibility complex Class I-restricted antimesothelioma cytotoxic T lymphocyte responses. The source of tumor-associated antigens for HLA-A2+ DCs from healthy donors was apoptotic HLA-A2– mesothelioma cells either lacking or expressing heat shock protein 70 according to whether tumor cells were heat shocked or not before ultraviolet-mediated apoptosis. Our results show that both apoptotic preparations were equivalent regarding the responsiveness of DCs to combined treatment with tumor necrosis factor-{alpha} and poly(inosinic-cytidylic) acid, as determined by similar increased expression of costimulatory molecules and interleukin-12 production. However, only DCs loaded with apoptotic heat shock protein 70-expressing cells were found to be potent in vitro inducers of cytotoxic T lymphocyte activity against HLA-A2+ mesothelioma cells. Such elicited cytotoxic T lymphocytes also exhibit cytotoxic activity against an HLA-A2+ melanoma cell line, suggesting recognition of shared antigens. These findings therefore carry the potential of offering an alternative, promising approach for the therapy of patients with malignant pleural mesothelioma.

Key Words: apoptotic cells • dendritic cells • heat shock proteins • immunotherapy • mesothelioma




This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire
Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response
Cancer Res., June 15, 2008; 68(12): 4882 - 4892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. May, T. Dao, J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, R. H. Zhang, P. Maslak, and D. A. Scheinberg
Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells
Clin. Cancer Res., August 1, 2007; 13(15): 4547 - 4555.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Scherpereel, B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M.-C. Copin, P. Devos, B. Chahine, H. Porte, and P. Lassalle
Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1155 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht
Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells
Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. D. Bradley, Y. E. Miller, F. J. Martinez, D. C. Angus, W. MacNee, and E. Abraham
Interstitial Lung Disease, Lung Cancer, Lung Transplantation, Pulmonary Vascular Disorders, and Sleep-disordered Breathing in AJRCCM in 2004
Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 675 - 685.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society